Sang-Hoon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sang-Hoon Kim has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Albert Price
International AIDs Vaccine Initiative (IAVI), 125 Broad Street, 9th Floor, New York, NY 10004, USA
1 shared publication - Daniel Craig
International AIDs Vaccine Initiative (IAVI), 125 Broad Street, 9th Floor, New York, NY 10004, USA
1 shared publication - Eu-Min Kim
SK bioscience Co., Ltd., 38, Yeongudanji-ro, Yeonsu-gu, Incheon 13493, Republic of Korea
1 shared publication - Jinhwan Shin
SK bioscience Co., Ltd., 38, Yeongudanji-ro, Yeonsu-gu, Incheon 13493, Republic of Korea
1 shared publication - Jun-Hong Jang
SK bioscience Co., Ltd., 38, Yeongudanji-ro, Yeonsu-gu, Incheon 13493, Republic of Korea
1 shared publication - Lauren Carter
Institute for Protein Design (IPD), University of Washington, 330 Yale Ave North, Seattle, WA 98109, USA
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1110
Scalable Production of a De Novo SARS-CoV-2 Antiviral Miniprotein in Escherichia coli
Background/Objectives: The rapid emergence of SARS-CoV-2 variants that evade neutralizing antibodies underscores the need for new antiviral biologics that integrate precise molecular design with scalable, cost-effective manufacturing. Computationally designed miniproteins targeting the spike protein’s receptor-binding domain (RBD) offer a promising alternative to monoclonal antibodies because of their small size, high thermal stability, and compatibility with microbial expression systems. Here, we detail the full development and cGMP manufacturing of IPD-52520, a novel antiviral miniprotein produced using an optimized E. coli platform. Methods: Two candidate miniproteins, a homotrimeric construct (Trimer, IPD-52520, 17 kDa) and a tandem fusion construct (Daisy, IPD-52521, 25 kDa), were evaluated in parallel through systematic optimization of strain selection, media formulation, fed-batch fermentation, inclusion-body solubilization, refolding, and chromatographic purification. The leading candidate was scaled from 5 L to 50 L under cGMP conditions, and biophysical and stability analyses were conducted to support nonclinical and Phase 1 clinical development. Results: The Trimer was selected as the lead molecule based on superior preclinical efficacy, favorable pharmacokinetics, and higher volumetric yields. The optimized process yields about 2 g/L of purified protein at over 90% purity. Scale-up from 5 L to 50 L demonstrated excellent batch consistency across six independent runs. Biophysical studies confirmed a well-folded, predominantly alpha-helical trimer (Tm = 73.4 °C; polydispersity = 1.005) with an intact primary structure and strong target binding (KD < 1 pM). Stability studies show the drug remains stable at 2–8 °C for at least 12 months, with ongoing long-term studies. Conclusions: These findings demonstrate that computationally designed antiviral miniproteins can be translated into scalable biologics and establish a platform for rapid therapeutic development against current and future pandemics.
- 3 September 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1110
Open AccessScalable Production of a De Novo SARS-CoV-2 Antiviral Miniprotein in Escherichia coli
Background/Objectives: The rapid emergence of SARS-CoV-2 variants that evade neutralizing antibodies underscores the need for new antiviral biologics that integrate precise molecular design with scalable, cost-effective manufacturing. Computationally designed miniproteins targeting the spike protein’s receptor-binding domain (RBD) offer a promising alternative to monoclonal antibodies because of their small size, high thermal stability, and compatibility with microbial expression systems. Here, we detail the full development and cGMP manufacturing of IPD-52520, a novel antiviral miniprotein produced using an optimized E. coli platform. Methods: Two candidate miniproteins, a homotrimeric construct (Trimer, IPD-52520, 17 kDa) and a tandem fusion construct (Daisy, IPD-52521, 25 kDa), were evaluated in parallel through systematic optimization of strain selection, media formulation, fed-batch fermentation, inclusion-body solubilization, refolding, and chromatographic purification. The leading candidate was scaled from 5 L to 50 L under cGMP conditions, and biophysical and stability analyses were conducted to support nonclinical and Phase 1 clinical development. Results: The Trimer was selected as the lead molecule based on superior preclinical efficacy, favorable pharmacokinetics, and higher volumetric yields. The optimized process yields about 2 g/L of purified protein at over 90% purity. Scale-up from 5 L to 50 L demonstrated excellent batch consistency across six independent runs. Biophysical studies confirmed a well-folded, predominantly alpha-helical trimer (Tm = 73.4 °C; polydispersity = 1.005) with an intact primary structure and strong target binding (KD < 1 pM). Stability studies show the drug remains stable at 2–8 °C for at least 12 months, with ongoing long-term studies. Conclusions: These findings demonstrate that computationally designed antiviral miniproteins can be translated into scalable biologics and establish a platform for rapid therapeutic development against current and future pandemics.